ClinConnect ClinConnect Logo
Search / Trial NCT06042296

Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Launched by BALIKESIR UNIVERSITY · Sep 15, 2023

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Pcna, Cd44 E Cadherin Immunohistochemistry Pterygium

ClinConnect Summary

This clinical trial is studying a condition called pterygium, which is a growth of tissue on the eye that can cause vision problems. Researchers want to learn more about certain proteins, like CD44, PCNA, and E-cadherin, that may play a role in how pterygium develops and comes back after treatment. Understanding these proteins could help improve how pterygium is treated in the future.

If you have pterygium and are interested in participating, you may be eligible for this study. However, individuals with a similar condition called pseudopterygium cannot take part. Since the trial is not yet recruiting participants, you will need to wait until it starts to find out more about what being a participant involves. This trial aims to gather information that could help better manage this eye condition and improve patient care.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria: patient with pterygium -
  • Exclusion Criteria: patient with pseudopterygium
  • -

About Balikesir University

Balikesir University is a prominent educational institution in Turkey, recognized for its commitment to advancing research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to facilitate rigorous and ethical research studies aimed at improving healthcare outcomes. Balikesir University collaborates with a diverse range of stakeholders, including healthcare professionals and industry partners, to drive clinical advancements and contribute to the global body of medical knowledge. Through its dedication to scientific excellence and patient safety, Balikesir University plays a vital role in the development of new therapies and treatment modalities.

Locations

Balıkesir, , Turkey

Patients applied

0 patients applied

Trial Officials

HÜMEYRA YILDIRIM

Principal Investigator

Balıkesir Medical Faculty

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported